^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    15d
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    20d
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    20d
    BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia (ACTRN12617000084381)
    P2, N=30, Completed, Australasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed
    Trial completion
    |
    CD19 positive
    |
    cytarabine • Blincyto (blinatumomab) • methotrexate
    27d
    Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. (PubMed, Cell)
    We further introduce a CAR incorporating an immunoglobulin G (IgG) Fc domain that recruits host Fc receptor-expressing phagocytes, enables T cell priming across major histocompatibility complex (MHC) mismatch, and enhances efficacy in immunocompetent allogeneic cancer models. Together, these findings establish expandable GMPs as a scalable platform for engineered immunotherapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MPO (Myeloperoxidase)
    |
    CD19 positive • EGFR positive
    29d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1m
    Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure (clinicaltrials.gov)
    P=N/A, N=686, Completed, Charite University, Berlin, Germany | Recruiting --> Completed | N=200 --> 686
    Trial completion • Enrollment change
    |
    CD19 positive
    1m
    Identifying Ultra-High Risk Large B-Cell Lymphoma Patients for Early Treatment with Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY Study (ACTRN12625000673448)
    P2, N=120, Recruiting, Australasian Leukaemia and Lymphoma Group | Not yet recruiting --> Recruiting | N=24 --> 120
    Enrollment open • Enrollment change • Trial initiation date
    |
    CD19 positive
    |
    cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    1m
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Phase classification: P1/2 --> P1
    Phase classification
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    1m
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    1m
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CD20 negative
    1m
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive